NeuraLight is a developer of neurology software intended to help patients affected by neurological disorders. The company is based in Austin, Texas, and Tel Aviv, Israel. This platform offers a proprietary, de-identified oculometric database to attain subpixel resolution using just a standard smartphone or webcam. Enabling clinicians with neurological screening, diagnosis, and care is highly personal and dependent on hand-operated examination with many signs and symptoms that are non-trivial to extract.
NeuraLight was funded $5.5 million led by Breakstone, with Operator Partners, MSAD, VSC Ventures, Kli, Tuesday, and Angel investors include Instacart CEO Fidji Simo, Clover Health CEO Vivek Garipalli, and Noam Solomon, the CEO of Immunai.
The new seed funding intends to advance drug development for neurological disorders and decrease development costs. The company also strives to help pharma companies reduce their time for drugs to enter the market.
NeuraLight aims to support people experiencing neurological disorders by digitizing neurological evaluation and care. Breakstone and Benami have hired talent from the research and pharmaceutical industries.
The team has developed a platform that automatically extracts microscopic eye movement measurements as reliable digital endpoints for neurological disorders. In addition, the platform can remove light and movement from videos using AI and machine learning to get a more precise video. The forum is ultimately meant to help accelerate clinical trials and increase the probability of prospective therapies for Parkinson’s, Multiple Sclerosis, Alzheimer’s, and other neurodegenerative diseases.
Breakstone says there aren’t numerous contenders within that term and that those that do need dedicated devices, such as camera eye-trackers and pupilometers. He notes that NeuraLight, aside from these companies, is that its platform only relies on video from a regular smartphone or webcam. The company has presented a passing patent to protect the technology that it’s developing.
NeuraLight records that more than 1 billion people globally suffer from neurological disorders. Unfortunately, current neurological evaluation is highly subjective and depends on a manual examination of symptoms, which is why pharmaceutical companies haven’t had practical tools to develop precise therapies.
Breakstone said they want to transform neurology entirely and allow the new generation of drugs to be developed. So, we made sure to hire and bring on people that care about changing the environment and want to help us create an iconic company that will transform the way neurological care evaluation is done today.
By: K. Tagura
Author statement:
Funded.com is the leading platform for accredited investors network worldwide. We monitor and provide updates on important funding events. Angel Investors and Venture Funding can be a key growth for a startup or existing business. Whether it is a first, second or third round financing having a strategic alliance with an Angel Investor or Venture Capital financing can propel a business to the next level and give the competitive edge.
Rss Feed
